Stock comparison
Haemonetics
Veeva Systems
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
VEEV
Veeva Systems
Market cap
$26.07B
Sector
Healthcare
Overall winner
Veeva Systems VEEV
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | VEEV | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 66B | HAE |
| Benjamin Graham | 85A | 81A | HAE |
| Philip Fisher | 60C | 77B | VEEV |
| Peter Lynch | 54C | 60C | VEEV |
| Joel Greenblatt | 31F | 52C | VEEV |
| Charlie Munger | 54D | 62C | VEEV |
| Terry Smith | 55D | 65D | VEEV |
Side-by-side metrics
| Metric | HAE | VEEV |
|---|---|---|
| Market cap | $2.98B | $26.07B |
| P/E (TTM) | 24.8x | 28.7x |
| EV/EBIT | 14.1x | 26.9x |
| ROIC (TTM) | 8.37% | 9.48% |
| Gross margin | 55.74% | 75.53% |
| Net margin | 7.29% | 28.44% |
| Revenue CAGR 5y | 7.65% | 14.63% |
| EPS CAGR 5y | 24.62% | 18.76% |
| Debt / Equity | 1.5x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 26.9x+47%
- EPS CAGR 5y24.62%vs 18.76%+24%
- P/E (TTM)24.8xvs 28.7x+14%
VEEV leads on
- Debt / Equity0.0xvs 1.5x+99%
- Market cap$26.07Bvs $2.98B+89%
- Net margin28.44%vs 7.29%+74%
- Revenue CAGR 5y14.63%vs 7.65%+48%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.